论文部分内容阅读
目的观察培哚普利治疗慢性肾病的临床效果。方法慢性肾病患者132例,随机分为研究组和对照组各66例。对照组给予环磷酰胺辅以糖皮质激素冲击治疗,研究组在对照组基础上加用培哚普利,疗程均为24周。比较两组临床疗效,治疗前后24 h尿蛋白定量及不良反应。采用SPSS 18.0统计软件,计量资料组间比较采用t检验,计数资料比较采用x~2检验。P≤0.05为差异有统计学意义。结果研究组总有效率为92.42%,对照组为74.24%,差异有统计学意义(x~2=7.854、P<0.05);研究组治疗前后24 h尿蛋白为(2.67+1.14)、(0.64+0.52)g,差异有统计学意义(t=13.161、P<0.05);对照组治疗前后24 h尿蛋白为(2.71+1.12)、(0.97+0.68)g,差异有统计学意义(t=10.788、P<0.05);研究组治疗后24 h尿蛋白低于对照组,差异有统计学意义(t=3.131、P<0.05)。研究组不良反应发生率为27.27%,对照组未出现明显不良反应。结论培哚普利治疗慢性肾病效果好,无严重不良反应。
Objective To observe the clinical effect of perindopril in the treatment of chronic kidney disease. Methods 132 patients with chronic kidney disease were randomly divided into study group and control group of 66 cases. The control group was given cyclophosphamide supplemented with glucocorticoid impact treatment. The study group was given perindopril on the basis of the control group, and the course of treatment was 24 weeks. The clinical curative effect was compared between the two groups before and after 24 h urinary protein quantitative and adverse reactions. Using SPSS 18.0 statistical software, measurement data were compared between groups using t test, count data were compared using x ~ 2 test. P≤0.05 for the difference was statistically significant. Results The total effective rate was 92.42% in the study group and 74.24% in the control group, the difference was statistically significant (x 2 = 7.854, P <0.05); the urinary protein in the study group was (2.67 + 1.14) +0.52) g, the difference was statistically significant (t = 13.161, P <0.05). The urinary protein in the control group before and 24 hours after treatment was (2.71 + 1.12), (0.97 + 0.68) g, the difference was statistically significant (t = 10.788, P <0.05). The urinary protein in study group 24 hours after treatment was lower than that in control group, the difference was statistically significant (t = 3.131, P <0.05). The incidence of adverse reactions in the study group was 27.27%, no obvious adverse reactions in the control group. Conclusion The effect of perindopril in the treatment of chronic kidney disease is good without serious adverse reactions.